TPSTTempest Therapeutics, Inc.

TPST Stock Price, Valuation & Chart | Tempest Therapeutics, Inc.

Compare

$1.100+0.05 (+4.76%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology TPST intrinsic value TPST calculated fair value vs price

Overview Financials Dividends Ratios

TPST Historical price chart

TPST Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization17.58M

PE Ratio-0.18

EPS-6.01

Trading Volume125.71K

Today's High/Low1.12/1.05

Dividend Yield0.00

52 Week High/Low12.23/0.84

Shares Outstanding15.98M

TPST Financial Statement

TPST Analyst ratings

TPST Analysis & performance metrics

TPST Company profile

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are…

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha…

TPST Management team

Name

Position

Samuel Whiting M.D., Ph.D.

Executive Vice President, Chief Medical Officer and Head of R&D

Justin Trojanowski CPA

Corporate Controller, Treasurer & Principal Accounting Officer

Lindsay Young

Head of Human Resources

Stephen R. Brady J.D., LLMCEO

Chief Executive Officer, President & Director

Nicholas MaestasCFO

Chief Financial Officer, Head of Corporate Strategy & Secretary

Name

Position

Samuel Whiting M.D., Ph.D.

Executive Vice President, Chief Medical Officer and Head of R&D

Justin Trojanowski CPA

Corporate Controller, Treasurer & Principal Accounting Officer

Lindsay Young

Head of Human Resources

Stephen R. Brady J.D., LLMCEO

Chief Executive Officer, President & Director

Nicholas MaestasCFO

Chief Financial Officer, Head of Corporate Strategy & Secretary

Management Team

Samuel Whiting M.D., Ph.D.

Executive Vice President, Chief Medical Officer and Head of R&D

Justin Trojanowski CPA

Corporate Controller, Treasurer & Principal Accounting Officer

Lindsay Young

Head of Human Resources

Stephen R. Brady J.D., LLMCEO

Chief Executive Officer, President & Director

Nicholas MaestasCFO

Chief Financial Officer, Head of Corporate Strategy & Secretary

Management

Samuel Whiting M.D., Ph.D.

Executive Vice President, Chief Medical Officer and Head of R&D

Justin Trojanowski CPA

Corporate Controller, Treasurer & Principal Accounting Officer

Lindsay Young

Head of Human Resources

Stephen R. Brady J.D., LLMCEO

Chief Executive Officer, President & Director

Nicholas MaestasCFO

Chief Financial Officer, Head of Corporate Strategy & Secretary

Total 5 executives

TPST Frequently asked questions

What is Tempest Therapeutics, Inc. (TPST) Stock Price?

Current stock price of Tempest Therapeutics, Inc. (TPST) stock is $1.100. The stock price is +4.76% higher in the session. The intraday range can be seen from this page. Volume of Tempest Therapeutics, Inc. (TPST) stock is 125.71K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Tempest Therapeutics, Inc. (TPST) stock price going up or down today?

The stock price of Tempest Therapeutics, Inc. (TPST) can change with earnings, company news, and overall market sentiment. Tempest Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Tempest Therapeutics, Inc. stock expensive at its current price?

Whether Tempest Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TPST on this page is -0.18. EPS on this page is -6.01. Compare those figures with peers and growth expectations before deciding if the current Tempest Therapeutics, Inc. price is justified.

How has the stock price of Tempest Therapeutics, Inc. (TPST) performed historically?

Historical performance for Tempest Therapeutics, Inc. (TPST) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TPST reacted to past earnings and market events.

Should I buy Tempest Therapeutics, Inc. (TPST) stock, at this price?

Buying Tempest Therapeutics, Inc. (TPST) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.